MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)

著录项

• 来源
  《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第1期|共2页
• 作者

  Young Kim; Toyoaki Hida; Hiroshi Nokihara; Masashi Kondo; Koichi Azuma; Takashi Seto; Yuichi Takiguchi; Makoto Nishio; Hiroshige Yoshioka; Fumio Imamura; Katsuyuki Hotta; Satoshi Watanabe; Koichi Goto; Kazuhiko Nakagawa; Tetsuya Mitsudomi; Nobuyuki Yamamoto; Hiroshi Kuriki; Ryoichi Asabe; Tomohiro Tanaka; Tomohide Tamura;

  展开▼
• 作者单位

  Kyoto University;

  Aichi Cancer Center Hospital;

  Department of Thoracic Oncology National Cancer Center Hospital;

  Respiratory Medicine Nagoya University;

  Department of Internal Medicine Division of Respirology Neurology and Rheumatology Kurume;

  National Kyushu Cancer Center;

  Department of Medical Oncology Graduate School of Medicine Chiba University;

  The Cancer Institute Hospital of Japanese Foundation for Cancer Research;

  Kurashiki Central Hospital;

  Osaka Medical Center for Cancer and Cardiovascular Disease;

  Okayama University Hospital;

  Osaka Medical Center for Cancer and Cardiovascular Disease;

  Department of Thoracic Oncology National Cancer Center Hospital East;

  Kindai University Faculty of Medicine;

  Division of Thoracic Surgery Department of Surgery Kindai University Faculty of Medicine;

  Internal Medicine Wakayama Medical University;

  Chugai Pharmaceutical Co. Ltd;

  Chugai Pharmaceutical Co. Ltd;

  Clinical Science &

  Strategy Dept. Chugai Pharmaceutical Co. Ltd;

  St Luke'S International Hospital;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 肿瘤学;
• 关键词